Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ZENITH20
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- NCT03318939 ↗
- Terminated
- Spectrum Pharmaceuticals, Inc
- Focused
We haven't built an HCP commentary report on ZENITH20 (poziotinib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ZENITH20 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- NSCLC
- Interventions
- Poziotinib
- Arms
- Cohort 1: Poziotinib 16 mg · Experimental
- Cohort 2: Poziotinib 16 mg · Experimental
- Cohort 3: Poziotinib 16 mg · Experimental
- Cohort 4: Poziotinib 8 mg · Experimental
- Cohort 4: Poziotinib 16 mg · Experimental
- Cohort 5: Poziotinib 6 mg · Experimental
- Cohort 5: Poziotinib 8mg · Experimental
- Cohort 5: Poziotinib 10 mg · Experimental
- Cohort 5: Poziotinib 12 mg · Experimental
- Cohort 5: Poziotinib 16 mg · Experimental
- Cohort 6: Poziotinib 8 mg · Experimental
- Cohort 6: Poziotinib 16 mg · Experimental
- Cohort 7: Poziotinib 8 mg · Experimental
- Cohort 7: Poziotinib 16 mg · Experimental
- Enrollment
- 648
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Start
- Oct 11, 2017
- Primary completion
- Apr 3, 2023
- Results posted
- Yes
- Registry record
- NCT03318939 · updated Jun 12, 2026
Publications
linked from the registry- Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 Mar 1;40(7):710-718. doi: 10.1200/JCO.21.01323. Epub 2021 Nov 29. PubMed 34843401